Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Astatine-211-Labeled BC8-B10 Monoclonal Antibody as Reduced Intensity Conditioning for Nonmalignant Diseases
NCT04083183Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2020
- Primary completion
- Jan 2028
- Modality
- Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Graft rejection. Started Jun 2020; status: recruiting.
Beyond the preview
Go deeper on NCT04083183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083183.